- Home
- KLTOW vs USAC Comparison
KLTOW vs USAC Comparison
Compare KLTOW & USAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTOW
- USAC
- Stock Information
- Founded
- KLTOW N/A
- USAC 1998
- Country
- KLTOW United States
- USAC United States
- Employees
- KLTOW 3
- USAC N/A
- Industry
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- USAC Natural Gas Distribution
- Sector
- KLTOW Health Care
- USAC Utilities
- Exchange
- KLTOW Nasdaq
- USAC Nasdaq
- Market Cap
- KLTOW N/A
- USAC N/A
- IPO Year
- KLTOW 2022
- USAC N/A
- Fundamental
- Price
- KLTOW $0.41
- USAC $24.91
- Analyst Decision
- KLTOW
- USAC Hold
- Analyst Count
- KLTOW 0
- USAC 4
- Target Price
- KLTOW N/A
- USAC $26.00
- AVG Volume (30 Days)
- KLTOW N/A
- USAC 372.2K
- Earning Date
- KLTOW N/A
- USAC 08-05-2025
- Dividend Yield
- KLTOW N/A
- USAC 8.43%
- EPS Growth
- KLTOW N/A
- USAC 67.81
- EPS
- KLTOW N/A
- USAC 0.67
- Revenue
- KLTOW N/A
- USAC $966,407,000.00
- Revenue This Year
- KLTOW N/A
- USAC $6.58
- Revenue Next Year
- KLTOW N/A
- USAC $4.94
- P/E Ratio
- KLTOW N/A
- USAC $37.11
- Revenue Growth
- KLTOW N/A
- USAC 10.03
- 52 Week Low
- KLTOW N/A
- USAC $21.06
- 52 Week High
- KLTOW N/A
- USAC $30.10
- Technical
- Relative Strength Index (RSI)
- KLTOW N/A
- USAC 46.62
- Support Level
- KLTOW N/A
- USAC $24.71
- Resistance Level
- KLTOW N/A
- USAC $25.44
- Average True Range (ATR)
- KLTOW 0.00
- USAC 0.65
- MACD
- KLTOW 0.00
- USAC -0.08
- Stochastic Oscillator
- KLTOW 0.00
- USAC 11.17
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.